New Delhi, May 2 (PTI): Ranbaxy Laboratories is recalling 29,790 packs of an anti-allergy drug in the US, manufactured by its arm Ohms Laboratories, because of defective packaging.
According to the US Food and Drug Administration (USFDA), Ohms Laboratories started the voluntary recall in February.
“An unacceptable level of blister defects have been identified in Loratadine and Pseudoephedrine Sulfate Extended release tablets, 10 mg/240 mg,” the USFDA said.
The recall comes at a time the US regulator has banned all the four plants of Ranbaxy in India from exporting drugs.
In January, the USFDA prohibited Ranbaxy from providing active pharmaceutical ingredients from Toansa plant in Punjab to other companies, including other Ranbaxy facilities, that make products for American consumers.
The USFDA slapped an import alert on Ranbaxy’s Mohali plant in Punjab for violating good manufacturing norms last September. Ranbaxy’s key facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh have been under a US import alert since 2008.
Last year in May, Ranbaxy pleaded guilty to “felony charges” related to the manufacture and distribution of certain “adulterated” drugs made at Dewas and Paonta Sahib and agreed to pay $500 million to the US as penalty.